None
Quote | Neon Therapeutics Inc. (NASDAQ:NTGN)
Last: | $3.07 |
---|---|
Change Percent: | 8.1% |
Open: | $2.96 |
Close: | $3.07 |
High: | $3.09 |
Low: | $2.915 |
Volume: | 3,604,103 |
Last Trade Date Time: | 05/05/2020 04:47:24 am |
News | Neon Therapeutics Inc. (NASDAQ:NTGN)
Achilles Therapeutics has filed proposed terms for a $176 million U.S. IPO. The firm is developing treatment candidates for various cancers. ACHL won't have data readout until the second half of 2022 for its Phase 1 safety trials, so the IPO may be more suited to institutional inv...
Quick Take CureVac ( CVAC ) intends to raise $200 million from the sale of its common stock in an IPO, plus another $118 million from a concurrent private placement, according to an amended registration statement . The company is advancing a number of drug development and gene therapy pro...
Message Board Posts | Neon Therapeutics Inc. (NASDAQ:NTGN)
Subject | By | Source | When |
---|---|---|---|
* * $NTGN Video Chart 04-22-2020 * * | ClayTrader | investorshub | 04/22/2020 10:57:13 PM |
Neon Therapeutics News:$ NTGN Stock Rockets 38% on | Rsarabjit | investorshub | 01/16/2020 9:52:17 PM |
* * $NTGN Video Chart 01-16-2020 * * | ClayTrader | investorshub | 01/16/2020 9:48:20 PM |
Bought a position today w/ $NTGN .. | bakedog38 | investorshub | 01/16/2020 9:11:25 PM |
weeeeeee | Crazy Money | investorshub | 01/16/2020 1:44:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Neon Therapeutics Inc. Company Name:
NTGN Stock Symbol:
NASDAQ Market:
Neon Therapeutics Inc. Website:
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon...
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020 COVID-19 vaccine program BNT162 set to enter the clinic in April 2020 Ended 2019 with cash equivalents of $583 million ( €520 millio...
NEW YORK, NY / ACCESSWIRE / February 13, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Forescout Technologies, Inc. (NASDAQ: FSCT )...